Dare Bioscience (DARE) Receivables - Other (2017 - 2025)
Dare Bioscience's (DARE) quarterly Receivables - Other came in at $191851.0 in Q4 2025, up 166.41% YoY from $72014.4 in Q4 2024, and down 48.03% on a QoQ basis from $369157.0 in Q3 2025.
Dare Bioscience (DARE) Receivables - Other (2017 - 2025) Analysis & Trends
Dare Bioscience (DARE) has 9 years of Receivables - Other data on file, last reported at $191851.0 in Q4 2025.
- Quarterly Receivables - Other rose 166.41% year-over-year to $191851.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$402348.0 (down 480.9% YoY) and the FY2025 annual result came in at $573061.0, up 179.68% from the prior year.
- Receivables - Other retreated to $191851.0 in Q4 2025, from $369157.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $3.0 million in Q2 2021 to a low of -$588882.0 in Q4 2022.
- A 5-year average of $851791.4 and a median of $545676.0 in 2023 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2021 — Receivables - Other soared 1568.48% — and 2022, when it tumbled 159.54%.
- Tracing DARE's Receivables - Other over 5 years: stood at $989070.0 in 2021, then tumbled by 159.54% to -$588882.0 in 2022, then jumped by 69.34% to -$180547.0 in 2023, then slumped by 60.02% to -$288904.0 in 2024, then surged by 166.41% to $191851.0 in 2025.
- The last three Receivables - Other figures came in at $191851.0 (Q4 2025), $369157.0 (Q3 2025), and $188116.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - |
| 10 | Dare Bioscience | 12.21 Mn | -406,442.64 | -132,343.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 191,851.00 |
| Dec 31, 2025 | 191,851.00 |
| Sep 30, 2025 | 369,157.00 |
| Sep 30, 2025 | 369,157.00 |
| Jun 30, 2025 | 188,116.00 |
| Jun 30, 2025 | 188,116.00 |
| Mar 31, 2025 | -124,748.00 |
| Mar 31, 2025 | -124,748.00 |
| Dec 31, 2024 | -288,904.00 |
| Dec 31, 2024 | -288,904.00 |
| Sep 30, 2024 | 518,886.00 |
| Sep 30, 2024 | 518,886.00 |
| Jun 30, 2024 | 902,174.00 |
| Jun 30, 2024 | 902,174.00 |
| Mar 31, 2024 | 1.39 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Dec 31, 2023 | -180,547.00 |
| Dec 31, 2023 | -180,547.00 |
| Sep 30, 2023 | 1.13 Mn |
| Sep 30, 2023 | 1.13 Mn |